
|Videos|November 23, 2021
Dr. Bander on PSMA breakthroughs in prostate cancer
Author(s)Urology Times staff
“Our preclinical therapy models all show us that the combination of the 2 agents [alpha and beta particles] is substantially superior to either agent alone,” says Neil H. Bander, MD.
Advertisement
In this video, Neil H. Bander, MD, discusses PSMA therapeutic innovations for patients with prostate cancer and how they will change diagnosis and treatment. Bander is the Bernard & Josephine Chaus professor of urologic oncology at Weill Cornell Medicine, New York City, New York.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5


















